With another warm reception predicted for biopharma IPOs in 2015, three more companies are looking to take advantage and enter the public arena. San Diego-based Tracon Pharmaceuticals Inc. is developing chimeric antibodies for cancer and age-related macular degeneration therapies and has filed to raise $58 million from its offering.